What does a prescriber think of biosimilars?
Author:
- 16 May 2011
- journal article
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 13 (5) , 234-238
Abstract
Le prescripteur, jusqu’à récemment, était confronté aux génériques, des molécules simples, relativement faciles à reproduire. Mais cet article illustre que la biodisponibilité des génériques reste une préoccupation. Et maintenant interviennent les biosimilaires. En cancérologie, les biosimilaires sont pour le moment limités aux érythropoïétines et aux facteurs de croissance des globules blancs. Bientôt, ils seront rejoints par des biosimilaires d’anticorps monoclonaux avec activité antitumorale. Le prescripteur doit se demander, comme pour les génériques, si ces produits ont bien la même action que les originaux, si leur sécurité d’emploi est la même, si la qualité de la production est garantie. Et il exigera que l’on puisse savoir si le patient a bien reçu le produit prescrit, et non pas un autre. Le prescripteur va aussi s’attacher à ce que le prixmoindre des biosimilaires permette vraiment de traiter les patients selon les recommandations internationales. Cela devrait être un bénéfice pour les patients et la communauté. Until recently the prescriber had to deal with generics, considered to be simple molecules which are easy to copy. But as discussed in this paper, the biodisponibility of generics remains a source of uncertainty. And now arrive biosimilars, limited for the time being in the cancer setting to granulocyte-colony stimulating factors (G-CSFs) and epoetins. Soon there will be biosimilar monoclonal antibodies with anticancer activity. The prescriber will ask, as for generics, if such drugs have the same activity as originators, if their safety profile is the same, if quality of the production process is guaranteed. The prescriber will want to know if the patient is indeed receiving the prescribed product, and not another. Finally the prescriber will want to check that the lower cost of biosimilars will allow to adhere to international guidelines. This should benefit patients and the community.Keywords
This publication has 23 references indexed in Scilit:
- Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropeniaJournal of Oncology Pharmacy Practice, 2011
- Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastimCritical Reviews in Oncology/Hematology, 2011
- Determinants of generic drug substitution in SwitzerlandBMC Health Services Research, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Trends in G-CSF use in 990 patients after EORTC and ASCO guidelinesEuropean Journal of Cancer, 2010
- GENERICS AND COST-EFFECTIVE PRESCRIBING IN BELGIUM: DOES BIOEQUIVALENCE ALWAYS TRANSLATE IN THERAPEUTIC EQUIVALENCE?Acta Clinica Belgica, 2009
- Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post‐marketing clinical study on healthy volunteersBritish Journal of Clinical Pharmacology, 2009
- Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN StudyEuropean Journal of Cancer Care, 2009
- Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND studyEuropean Journal of Cancer, 2009
- Promoting evidence-based management of anemia in cancer patients: Background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelinesCritical Reviews in Oncology/Hematology, 2008